The scale of the biopharmaceutical industry in the bonded zone reached 306 billion yuan (US$42.27 billion) in 2023, an increase of 7.3 percent over the previous year, accounting for nearly one-third of Shanghai's total, becoming an important support for Shanghai to build a world-class biopharmaceutical industry cluster with international influence.
On January 25, the Bard Medical Devices Distribution Center project under the BD Medical Group officially landed in the bonded zone. BD plans to establish the first self-operated medical device distribution center in China in the Pudong Airport Comprehensive Bonded Zone, which will meet Bard's business needs in the East China region for the next five to ten years.
"The bonded zone has been committed to addressing the practical needs of enterprise development, but what remains unchanged is that the bonded zone has always positioned itself as the 'government partner' of enterprises, growing and developing together with them," said Deng Jianmin, global senior vice president and general manager of Greater China of BD Medical.
Other global leaders in the biopharmaceutical industry that are advancing in the bonded zone include Eli Lilly Pharmaceuticals and Roche Diagnostics. In September this year, Roche Diagnostics' new headquarters will be completed and put into use in Pudong, carrying the new development of Roche Diagnostics in China for the next 10 years.
"In recent years, we have seen Pudong making continuous efforts to build a world-class biopharmaceutical industry cluster, with many new and groundbreaking policies being introduced, all of which have propelled the development of enterprises," said Yao Guoliang, general manager of Roche Diagnostics China.
Currently, the bonded zone has attracted 848 biopharmaceutical companies, covering the entire industry chain including research and development, testing, production, warehousing, trade, supply chain management, medical services and clinical trials.
